Discontinued — last reported Q4 '24
PEMAZYRE Royalty Revenues — Total revenues
Incyte PEMAZYRE Royalty Revenues — Total revenues decreased by 19.6% to $333.00K in Q4 2024 compared to the prior quarter. Year-over-year, this metric declined by 51.2%, from $683.00K to $333.00K. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market demand or expanded clinical use of the drug, while a decrease may signal market saturation, increased competition, or changes in royalty terms.
Detailed definition
This metric represents the total revenue recognized from royalty payments generated by the licensing or commercializatio...
Peer comparison
Comparable to royalty revenue streams reported by other biopharmaceutical companies for licensed oncology assets, often benchmarked against total product sales or licensing agreement performance.
incy_segment_pemazyre_royalty_revenues_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.21M | $412.00K | $349.00K | $523.00K | $683.00K | $548.00K | $876.00K | $414.00K | $333.00K |
| QoQ Change | — | — | — | — | — | — | — | -65.8% | -15.3% | +49.9% | +30.6% | -19.8% | +59.9% | -52.7% | -19.6% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | -43.3% | +33.0% | +151.0% | -20.8% | -51.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Incyte's pemazyre royalty revenues — total revenues?
- Incyte (INCY) reported pemazyre royalty revenues — total revenues of $333.00K in Q4 2024.
- How has Incyte's pemazyre royalty revenues — total revenues changed year-over-year?
- Incyte's pemazyre royalty revenues — total revenues decreased by 51.2% year-over-year, from $683.00K to $333.00K.
- What does pemazyre royalty revenues — total revenues mean?
- Total revenue earned from royalty payments on the sales of the oncology drug Pemazyre.